This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elias, N. Articles by Schonfeld, G. Search for Related Content PubMed PubMed Citation Articles by Elias, N. Articles by Schonfeld, G. Related Collections Biochemistry and metabolism Genetics of cardiovascular disease Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2714.)
© 1999 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Decreased Production Rates of VLDL Triglycerides and ApoB-100 in Subjects Heterozygous for Familial Hypobetalipoproteinemia

Nizar Elias; Bruce W. Patterson; Gustav Schonfeld

From the Division of Atherosclerosis, Lipid Research, and Nutrition and the Division of Gastroenterology (B.W.P.), Department of Internal Medicine, Washington University School of Medicine, St. Louis, Mo.

Correspondence to Gustav Schonfeld, MD, Department of Internal Medicine, Washington University School of Medicine, 660 S Euclid, Box 80466, St. Louis, MO 63110. E-mail gschonfe{at}imgate.wustl.edu

Abstract—Familial hypobetalipoproteinemia (FHBL) is an autosomal codominant disorder characterized by low levels of apolipoprotein (apo) B and low-density lipoprotein (LDL) cholesterol. Decreased production rates of apoB have been demonstrated in vivo in FHBL heterozygotes. In the present study, we wished to investigate whether the transport of triglycerides was similarly affected in these subjects. Therefore, we studied the in vivo kinetics of very-low-density lipoprotein (VLDL) triglycerides and VLDL apoB-100 simultaneously in 7 FHBL heterozygotes from 2 well-characterized kindreds and 7 healthy normolipidemic subjects. In both kindreds, hypobetalipoproteinemia is caused by mutations in the 5' portion of the apoB gene specifying short truncations of apoB undetectable in plasma. A bolus injection of deuterated palmitate and a primed constant infusion of deuterated leucine were given simultaneously, and their incorporation into VLDL triglycerides and VLDL apoB, respectively, were determined by gas chromatography–mass spectrometry. Kinetic parameters were calculated by using compartmental modeling. VLDL apoB fractional catabolic rates (FCRs) in FHBL heterozygotes and controls were similar (11.6±3.9 and 10.9±2.4 pools per day, respectively, P=0.72). On the other hand, FHBL heterozygotes had a 75% decrease in VLDL apoB production rates compared with normal subjects (5.8±1.8 versus 23.4±7.1 mg/kg per day, P<0.001). The decreased production rates of VLDL apoB accounts for the very low concentrations of plasma apoB found in heterozygotes from these kindreds (24% of normal). Mean VLDL triglyceride FCRs in FHBL subjects and controls were not significantly different (1.06±0.74 versus 0.89±0.50 pools per hour, respectively, P=0.61). There was a good correlation between VLDL apoB FCR and VLDL triglyceride FCR in the 2 groups (r=0.84, P<0.001). VLDL triglyceride production rates were decreased by 60% in FHBL heterozygotes compared with controls (9.3±6.0 versus 23.0±9.6 µmol/kg per hour, P=0.008). Thus, the hepatic secretion of VLDL triglycerides is reduced in FHBL heterozygotes but to a lesser extent than the decrease in apoB-100 secretion. This is probably achieved by the secretion of VLDL particles enriched with triglycerides.

Key Words: familial hypobetalipoproteinemia • apolipoprotein B • triglycerides • stable isotopes

This article has been cited by other articles:

				J. R. Burnett, S. Zhong, Z. G. Jiang, A. J. Hooper, E. A. Fisher, R. S. McLeod, Y. Zhao, P. H. R. Barrett, R. A. Hegele, F. M. van Bockxmeer, et al. Missense Mutations in APOB within the beta{alpha}1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia J. Biol. Chem., August 17, 2007; 282(33): 24270 - 24283. [Abstract] [Full Text] [PDF]

				A. J. Hooper, K. Robertson, P. H. R. Barrett, K. G. Parhofer, F. M. van Bockxmeer, and J. R. Burnett Postprandial Lipoprotein Metabolism in Familial Hypobetalipoproteinemia J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1474 - 1478. [Abstract] [Full Text] [PDF]

				R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753. [Abstract] [Full Text] [PDF]

				X. Lin, Z. Chen, P. Yue, M. R. Averna, R. E. Ostlund Jr., M. A. Watson, and G. Schonfeld A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1170 - G1176. [Abstract] [Full Text] [PDF]

				X. Lin, P. Yue, Y. Xie, N. O. Davidson, N. Sakata, R. E. Ostlund Jr., Z. Chen, and G. Schonfeld Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation Am J Physiol Gastrointest Liver Physiol, July 1, 2005; 289(1): G146 - G152. [Abstract] [Full Text] [PDF]

				A. J. Whitfield, P. H. R. Barrett, F. M. van Bockxmeer, and J. R. Burnett Lipid Disorders and Mutations in the APOB Gene Clin. Chem., October 1, 2004; 50(10): 1725 - 1732. [Abstract] [Full Text] [PDF]

				T. Tanoli, P. Yue, D. Yablonskiy, and G. Schonfeld Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity J. Lipid Res., May 1, 2004; 45(5): 941 - 947. [Abstract] [Full Text] [PDF]

				Z. Chen, R. L. Fitzgerald, G. Li, N. O. Davidson, and G. Schonfeld Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele J. Lipid Res., January 1, 2004; 45(1): 155 - 163. [Abstract] [Full Text] [PDF]

				G. Schonfeld Familial hypobetalipoproteinemia: a review J. Lipid Res., May 1, 2003; 44(5): 878 - 883. [Abstract] [Full Text] [PDF]

				J. R. Burnett, J. Shan, B. A. Miskie, A. J. Whitfield, J. Yuan, K. Tran, C. J. McKnight, R. A. Hegele, and Z. Yao A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia J. Biol. Chem., April 4, 2003; 278(15): 13442 - 13452. [Abstract] [Full Text] [PDF]

				Z. Chen, R. L. Fitzgerald, J. E. Saffitz, C. F. Semenkovich, and G. Schonfeld Amino Terminal 38.9% of Apolipoprotein B-100 Is Sufficient to Support Cholesterol-Rich Lipoprotein Production and Atherosclerosis Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 668 - 674. [Abstract] [Full Text] [PDF]

				G. Schonfeld, B. W. Patterson, D. A. Yablonskiy, T. S. K. Tanoli, M. Averna, N. Elias, P. Yue, and J. Ackerman Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis J. Lipid Res., March 1, 2003; 44(3): 470 - 478. [Abstract] [Full Text] [PDF]

				D. Y. Hung, F. J. Burczynski, P. Chang, A. Lewis, P. P. Masci, G. A. Siebert, Y. G. Anissimov, and M. S. Roberts Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites Am J Physiol Gastrointest Liver Physiol, March 1, 2003; 284(3): G423 - G433. [Abstract] [Full Text] [PDF]

				R. J. Neuman, B. Yuan, D. S. Gerhard, K.-Y. Liu, P. Yue, S. Duan, M. Averna, and G. Schonfeld Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds J. Lipid Res., March 1, 2002; 43(3): 407 - 415. [Abstract] [Full Text] [PDF]

				X. Lin, G. Schonfeld, P. Yue, and Z. Chen Hepatic Fatty Acid Synthesis Is Suppressed in Mice With Fatty Livers Due to Targeted Apolipoprotein B38.9 Mutation Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 476 - 482. [Abstract] [Full Text] [PDF]

				B. W. Patterson, B. Mittendorfer, N. Elias, R. Satyanarayana, and S. Klein Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover J. Lipid Res., February 1, 2002; 43(2): 223 - 233. [Abstract] [Full Text] [PDF]

				P. Tarugi, A. Lonardo, C. Gabelli, F. Sala, G. Ballarini, I. Cortella, L. Previato, S. Bertolini, R. Cordera, and S. Calandra Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene J. Lipid Res., October 1, 2001; 42(10): 1552 - 1561. [Abstract] [Full Text] [PDF]

				A. Carpentier, B. W. Patterson, K. D. Uffelman, A. Giacca, M. Vranic, M. S. Cattral, and G. F. Lewis The Effect of Systemic Versus Portal Insulin Delivery in Pancreas Transplantation on Insulin Action and VLDL Metabolism Diabetes, June 1, 2001; 50(6): 1402 - 1413. [Abstract] [Full Text]

				L. J. Wilcox, N. M. Borradaile, L. E. de Dreu, and M. W. Huff Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP J. Lipid Res., May 1, 2001; 42(5): 725 - 734. [Abstract] [Full Text]

				N. Elias, B. W. Patterson, and G. Schonfeld In Vivo Metabolism of ApoB, ApoA-I, and VLDL Triglycerides in a Form of Hypobetalipoproteinemia Not Linked to the ApoB Gene Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1309 - 1315. [Abstract] [Full Text] [PDF]

				Z. Chen, R. L. Fitzgerald, M. R. Averna, and G. Schonfeld A Targeted Apolipoprotein B-38.9-producing Mutation Causes Fatty Livers in Mice Due to the Reduced Ability of Apolipoprotein B-38.9 to Transport Triglycerides J. Biol. Chem., October 13, 2000; 275(42): 32807 - 32815. [Abstract] [Full Text] [PDF]